The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Clinical biomarkers in drug discovery and development
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Health Measurement Scales: A Practical Guide to Their Development and Use
Streiner, D. L., Norman, G. R., & Cairney, J. (1989) · Cited by 9,595
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · cited 1×
“The quality of evidence supporting the validity of a new biomarker has been described as similar to that used to support the validity of new therapie”
MethodAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Cited by
Fass, L. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.04.001 · Cited by 822
Multiplexed protein measurement: technologies and applications of protein and antibody arrays
Kingsmore, S. F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2006 · Cited by 715
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Self-citationWearable chemical sensors for biomarker discovery in the omics era
Sempionatto, J. R., Lasalde-Ramírez, J. A., Mahato, K., Wang, J., & Gao, W. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00439-w · Cited by 613
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Bickel, W. K., Koffarnus, M. N., Moody, L., & Wilson, A. G. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.013 · Cited by 386
Cell-penetrating peptides as delivery vehicles for biology and medicine
Stewart, K. M., Horton, K. L., & Kelley, S. O. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b719950c · Cited by 381
Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery
Peterson, J. T. (2004) · Heart Failure Reviews · doi:10.1023/b:hrev.0000011395.11179.af · Cited by 370
Cellular imaging in drug discovery
Lang, P., Yeow, K., Nichols, A., & Scheer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2008 · Cited by 351
Drucker, E., & Krapfenbauer, K. (2013) · EPMA Journal · doi:10.1186/1878-5085-4-7 · Cited by 349
The importance of the domain of applicability in QSAR modeling
Weaver, S., & Gleeson, M. P. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.01.002 · Cited by 338
High‐field magnetic resonance imaging of brain iron: birth of a biomarker?
Schenck, J. F., & Zimmerman, E. A. (2004) · NMR in Biomedicine · doi:10.1002/nbm.922 · Cited by 337
Bodaghi, A., Fattahi, N., & Ramazani, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13323 · Cited by 336
RetractedDrug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
Structural connectomics in brain diseases
Griffa, A., Baumann, P. S., Thiran, J.-P., & Hagmann, P. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.056 · Cited by 308
Idiosyncratic Drug Reactions: Current Understanding
Uetrecht, J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105150 · Cited by 304
Development of biomarkers in multiple sclerosis
Bielekova, B., & Martin, R. (2004) · Brain · doi:10.1093/brain/awh176 · Cited by 299
Metabolomics: from pattern recognition to biological interpretation
Weckwerth, W., & Morgenthal, K. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03609-3 · Cited by 298
Discovery of Protein Biomarkers for Renal Diseases
Hewitt, S. M., Dear, J., & Star, R. A. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000129114.92265.32 · Cited by 295
The peripheral-blood transcriptome: new insights into disease and risk assessment
Mohr, S., & Liew, C.-C. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.003 · Cited by 295
Drug–Target Kinetics in Drug Discovery
Tonge, P. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00185 · Cited by 287
Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Consensus on biomarkers for neuroendocrine tumour disease
Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00186-2 · Cited by 283
Wiener, M. C., Sachs, J. R., Deyanova, E. G., & Yates, N. A. (2004) · Analytical Chemistry · doi:10.1021/ac0493875 · Cited by 275
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
Engineered nanoparticles for biomolecular imaging
Mahmoudi, M., Serpooshan, V., & Laurent, S. (2011) · Nanoscale · doi:10.1039/c1nr10326a · Cited by 262
The role of analytical sciences in medical systems biology
Greef, J. V. D., Stroobant, P., & Heijden, R. V. D. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.08.013 · Cited by 262
Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Redon, C. E., Nakamura, A. J., Zhang, Y.-W., Ji, J. (., Bonner, W. M., Kinders, R. J., Parchment, R. E., Doroshow, J. H., & Pommier, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0523 · Cited by 255
Frey, B. N., Andreazza, A. C., Houenou, J., Jamain, S., Goldstein, B. I., Frye, M. A., Leboyer, M., Berk, M., Malhi, G. S., Lopez-Jaramillo, C., et al. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413478217 · Cited by 234
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
Chamberlain, S. R., Robbins, T. W., Winder-Rhodes, S., Müller, U., Sahakian, B. J., Blackwell, A. D., & Barnett, J. H. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.019 · Cited by 178
From maps to multi-dimensional network mechanisms of mental disorders
Braun, U., Schaefer, A., Betzel, R. F., Tost, H., Meyer-Lindenberg, A., & Bassett, D. S. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.007 · Cited by 177
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems
Kaalep, A., Sera, T., Oyen, W., Krause, B. J., Chiti, A., Liu, Y., & Boellaard, R. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3853-7 · Cited by 174
Feasibility of state of the art PET/CT systems performance harmonisation
Kaalep, A., Sera, T., Rijnsdorp, S., Yaqub, M., Talsma, A., Lodge, M. A., & Boellaard, R. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3977-4 · Cited by 160
In Vivo mouse imaging and spectroscopy in drug discovery
Beckmann, N., Kneuer, R., Gremlich, H., Karmouty‐Quintana, H., Blé, F., & Müller, M. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1153 · Cited by 118
Hargreaves, R., Ferreira, J. C. A., Hughes, D., Brands, J., Hale, J., Mattson, B., & Mills, S. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05961.x · Cited by 102
Self-citationFusion of nonclinical and clinical data to predict human drug safety
Johnson, D. E. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.3 · Cited by 9
Metadata
- Authors
- Frank, R., & Hargreaves, R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-07
- Volume
- 2
- Issue
- 7
- Pages
- 566-580
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2000980666
- Cited by
- 794
- References
- 142
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.